Furthermore, treatment with the specific inhibitor Herceptin in HER-2-positive breast cancer has been shown to markedly reduce PGK1 protein expression, thereby effectively inhibiting the proliferation of breast cancer cells. This evidence concerns the gene ERBB2 and breast carcinoma.